Drug intelligence / Profile preview

Symbiter-Omega

Development stage: Unknown
Lead developer: O.D. Prolisok
Modality: Live Biotherapeutic Products → Microbiome Therapeutics, Small Molecules
Administration: Oral

Overview

Symbiter-Omega is a combination therapeutic consisting of the multiprobiotic "Symbiter" and omega-3 polyunsaturated fatty acids (PUFAs) derived from flax and wheat germ oils. The Symbiter component is a concentrated biomass of 14 probiotic bacterial genera, including *Lactobacillus*, *Bifidobacterium*, *Propionibacterium*, and *Acetobacter*. This combination is designed to address metabolic and inflammatory conditions by modulating the gut microbiota and utilizing the lipid-regulating and anti-inflammatory properties of omega-3 fatty acids. Clinical research has demonstrated its efficacy in reducing hepatic steatosis in non-alcoholic fatty liver disease (NAFLD) and improving insulin sensitivity, glycemic control, and obesity parameters in patients with type 2 diabetes.

Brand names: Symbiter-Omega
Other names: Symbiter + Omega-3multiprobiotic Symbiter with omega-3

Targets

PPARA (Peroxisome proliferator-activated receptor alpha)TNFA (Tumor necrosis factor alpha (soluble))

Beyond the preview

Go deeper on Symbiter-Omega.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Symbiter-Omega.